Cancer Management and Research (Dec 2020)

Thirty-Day Mortality After Curative and Palliative Anti-Cancer Treatment: Data Interpretation and Lessons for Clinical Implementation

  • Tashkandi E,
  • Basulaiman B,
  • Alghareeb W,
  • Hamadi F,
  • Alghamdi A,
  • Albabakri F,
  • Alshabi R,
  • Jaffal M,
  • Albaradie A,
  • Azher R

Journal volume & issue
Vol. Volume 12
pp. 12301 – 12308

Abstract

Read online

Emad Tashkandi,1,2 Bassam Basulaiman,3 Waleed Alghareeb,3 Faris Hamadi,3 Anas Alghamdi,3 Faez Albabakri,2 Redhwan Alshabi,2 Mohammad Jaffal,2 Abdulrahman Albaradie,2 Ruqayya Azher4 1Umm AlQura University, College of Medicine, Makkah, Saudi Arabia; 2King Abdullah Medical City, Oncology Center, Makkah, Saudi Arabia; 3Comprehensive Cancer Center, Medical Oncology, King Fahad Medical City, Riyadh, Saudi Arabia; 4Umm Al-Qura University, Community Medicine Department, Makkah, Saudi ArabiaCorrespondence: Emad TashkandiUmm AlQura University, College of Medicine, 3829, Aljamiah, Makkah, Saudi ArabiaTel +966 555 29 0061Email [email protected]: Despite advancements in cancer therapeutics, mortality and morbidity due to anti-cancer treatments still occur but are not frequently reported. We aimed to report the 30-day mortality and morbidity of all curative and palliative anti-cancer treatments.Patients and Methods: Adults with solid and hematological malignancies from two large cancer centers in Saudi Arabia, irrespective of the cancer stage and treatment type, were included in this retrospective observational study.Results: Between December 1, 2019 and February 29, 2020, 1694 patients from King Abdullah Medical City in Makkah and King Fahad Medical City in Riyadh were included in the study. Among them, 77.5% were younger than 65 years of age; 72.8% were female; the prevalence of obesity, diabetes, and hypertension was 35%, 34%, and 28%, respectively; and 66.5% of patients had breast and gastrointestinal cancers. Fifty-nine (3.5%) patients died within 30 days of receiving anti-cancer treatment. Of them, 9 (0.3%) were treated with curative intent, and 50 (3%) were treated with palliative intent.Conclusion: Our results emphasize the need to address preventable metabolic changes and implement innovative, predictive, preventive, and personalized medicine (PPPM) approaches focusing on patient profiles. Reporting the 30-day outcomes of all anti-cancer treatments will also allow the identification of factors underlying mortality and morbidity and lead to an improvement in oncological outcomes via innovative programs designed to improve clinical decision-making.Keywords: cancer, chemotherapy, morbidity, individual outcome, predictive preventive personalized medicine

Keywords